One of the major successes of Hamied was building a strong US business, despite Cipla being a late entrant. Hamied said this was possible by pursuing selective yet complex generic portfolios. Cipla entered the US market in a big way with the strategic acquisitions of two generic companies, InvaGen Pharma and Exelan Pharma, for $550 million in 2015. From FY15 to FY21, Cipla’s US revenue grew close to five times. The US business contributed around one-fifth of the total revenue of ₹19,160 crore in FY21.
